MedPath

Pedometer Intervention and Health Effects for Sedentary Colorectal Cancer Patients During Adjuvant Chemotherapy

Not Applicable
Completed
Conditions
Colorectal Cancer
Interventions
Behavioral: Pedometer + hospital based intervention
Behavioral: Pedometer intervention
Device: Omron Walking Style pro. 20
Registration Number
NCT02522520
Lead Sponsor
Rigshospitalet, Denmark
Brief Summary

Colorectal cancer is one of the most common cancers in Denmark, annually 4,200 men and women are diagnosed and approx. 2000 patients die of their colorectal cancer. As with other cancers, the risk of colorectal cancer increases with age, and the median age at diagnosis is 71 years. Improved treatment has increased the number of survivors with an expected 5-year survival rate of 50-60%. Characteristic of this group of patients is that at the time of diagnosis they often live with comorbidities and have limited leisure time physical activity.

There is evidence that rehabilitation in the form of physical exercise for cancer patients after their initial treatment has a positive effect on a number of physical and psychological parameter such as health-related quality of life, physical capacity and physical function, fatigue, anxiety and depression. However, the most frequently studied diagnosis group is women with breast cancer. Until now only few studies have evaluated the effects of physical activity among colorectal cancer patients receiving chemotherapy

The purpose of this study is: to examine the effect of two different training initiatives - 12 weeks progressive, high-intensity training versus low intensity exercise intervention - on physical, emotional and social habitus, in sedentary patients with colorectal cancer during adjuvant chemotherapy.

The hypothesis of the study are: 1. That both interventions will show a positive association between increased physical capacity (measured by aerobic capacity VO2-peak / peak oxygen uptake) and improved physical function, reduced fatigue and anxiety in the included sedentary colorectal cancer patients undergoing adjuvant chemotherapy.

Participants: Patients undergoing adjuvant chemotherapy for colorectal cancer who have self-reported physical activity level below the national recommended levels (less than 150 min/week of moderate leisure time physical activity, and exercises at least 20 minutes of strenuous physical activity twice a week).

Benefits and risks of participating: Possible benefits of the interventions: to reduce treatment related symptoms and side-effects, increase vitality and well-being and promote lifestyle changes among sedentary colorectal cancer patients receiving adjuvant chemotherapy. At participation in the interventions minor sports injuries may occur.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
21
Inclusion Criteria
  • Diagnosed with colorectal cancer in adjuvant chemotherapy
  • Age 18+ years
  • WHO performance status of 0 or 1
  • Undergone surgery at least 6 weeks ago
  • Do not meet criteria for recommended physical activity level of 150 min / week of moderate leisure time physical activity, and exercises at least 20 minutes of strenuous physical activity twice a week.
Exclusion Criteria
  • Myocardial infarction within the past six months
  • Symptomatic heart failure
  • Known angina pectoris
  • Contraindication for moderate to strenuous physical activity

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Pedometer + hospital based interventionOmron Walking Style pro. 20Individual progressive pedometer intervention and 5 sessions supervised interval walking + followed by supervised hospital-based intervention of moderate to high-intensity Furthermore, the patients receive individual health counseling and symptom management counseling to support behavioral change towards increased physical activity.
Pedometer + hospital based interventionPedometer + hospital based interventionIndividual progressive pedometer intervention and 5 sessions supervised interval walking + followed by supervised hospital-based intervention of moderate to high-intensity Furthermore, the patients receive individual health counseling and symptom management counseling to support behavioral change towards increased physical activity.
Pedometer interventionPedometer interventionIndividual progressive pedometer intervention of low to moderate intensity. Furthermore, the patients receive individual health counseling and symptom management counseling to support behavioral change towards increased physical activity.
Pedometer interventionOmron Walking Style pro. 20Individual progressive pedometer intervention of low to moderate intensity. Furthermore, the patients receive individual health counseling and symptom management counseling to support behavioral change towards increased physical activity.
Primary Outcome Measures
NameTimeMethod
Maximum oxygen uptake - ( VO2 peak)12 weeks

Assessed with objective physiological test

Secondary Outcome Measures
NameTimeMethod
Symptoms and side-effectsFrom baseline to 39 weeks

Assessed by MD Andersen symptom questionnaire and The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, chemotherapy-induced peripheral neuropathy

Health related Quality of LifeFrom baseline to 39 weeks

Assessed by The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, specifically for colon cancer patients

Anxiety and DepressionFrom baseline to 39 weeks

Assessed by The Hospital Anxiety and Depression Scale

Lifestyle factorsFrom baseline to 39 weeks

Assessed by smoking cessation, alcohol, diet

Blood cholesterolsFrom baseline to 39 weeks

Assessed by blood samples

Physical activity levelFrom baseline to 39 weeks

Assessed by the International Physical Activity Questionnaire

Blood pressure / pulseFrom 6 to 12 weeks

Assessed by Heart Rate Monitor during the hospital-based intervention

Pedometer Step CountFrom baseline to 12 weeks

Assessed by Omron Walking Style pro. 20 with electronic data transmission

Dual Energy X-ray Absorptiometry scanFrom baseline to 39 weeks

Assessed by dual energy x-ray absorptiometry.

Trial Locations

Locations (1)

Rigshospitalet

🇩🇰

Copenhagen, Denmark

© Copyright 2025. All Rights Reserved by MedPath